ONCAlert | Upfront Therapy for mRCC
Videos  >  

Expert Discusses Practice-Changing Data From KATHERINE Trial in Breast Cancer

Mark D. Pegram, MD
Published Online:7:24 PM, Wed March 20, 2019

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses how the results from the phase III KATHERINE trial will change practice for the treatment of patients with breast cancer.

To date, Pegram says that physicians have had the option of using a second antibody in high-risk patients with early-stage disease. Now there is biological evidence to using these agents in the neoadjuvant setting and treatments can be tailored more based on their pathologic complete response, or lack thereof, says Pegram.

T-DM1 provides a new option for patients, replacing trastuzumab (Herceptin) and changing the treatment landscape dramatically.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.